- Home
- DOYU vs AKBA Comparison
DOYU vs AKBA Comparison
Compare DOYU & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOYU
- AKBA
- Stock Information
- Founded
- DOYU 2014
- AKBA 2007
- Country
- DOYU China
- AKBA United States
- Employees
- DOYU 1336
- AKBA N/A
- Industry
- DOYU Computer Software: Programming Data Processing
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- DOYU Technology
- AKBA Health Care
- Exchange
- DOYU Nasdaq
- AKBA Nasdaq
- Market Cap
- DOYU 352.1M
- AKBA 336.2M
- IPO Year
- DOYU 2019
- AKBA 2014
- Fundamental
- Price
- DOYU $10.88
- AKBA $1.82
- Analyst Decision
- DOYU Sell
- AKBA Strong Buy
- Analyst Count
- DOYU 4
- AKBA 2
- Target Price
- DOYU $7.03
- AKBA $5.75
- AVG Volume (30 Days)
- DOYU 136.9K
- AKBA 2.3M
- Earning Date
- DOYU 12-05-2024
- AKBA 11-07-2024
- Dividend Yield
- DOYU N/A
- AKBA N/A
- EPS Growth
- DOYU N/A
- AKBA N/A
- EPS
- DOYU N/A
- AKBA N/A
- Revenue
- DOYU $650,466,712.00
- AKBA $169,879,000.00
- Revenue This Year
- DOYU N/A
- AKBA N/A
- Revenue Next Year
- DOYU N/A
- AKBA $3.23
- P/E Ratio
- DOYU N/A
- AKBA N/A
- Revenue Growth
- DOYU N/A
- AKBA N/A
- 52 Week Low
- DOYU $6.29
- AKBA $0.80
- 52 Week High
- DOYU $20.17
- AKBA $2.48
- Technical
- Relative Strength Index (RSI)
- DOYU 58.62
- AKBA 68.47
- Support Level
- DOYU $10.53
- AKBA $1.30
- Resistance Level
- DOYU $11.13
- AKBA $2.01
- Average True Range (ATR)
- DOYU 0.52
- AKBA 0.12
- MACD
- DOYU 0.21
- AKBA 0.04
- Stochastic Oscillator
- DOYU 91.14
- AKBA 78.52
About DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.